|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040214872A1
(en)
|
2002-09-26 |
2004-10-28 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
JP2009520949A
(ja)
|
2005-11-16 |
2009-05-28 |
アンブルックス，インコーポレイテッド |
非天然アミノ酸を含んでいる組成物および方法
|
|
EP1968635B1
(en)
|
2005-12-14 |
2014-09-17 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CA2632832A1
(en)
|
2005-12-30 |
2007-07-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CN101384711A
(zh)
|
2006-01-19 |
2009-03-11 |
Ambrx公司 |
具有经调节的免疫原性的非天然氨基酸多肽
|
|
WO2008077079A1
(en)
|
2006-12-18 |
2008-06-26 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
KR20090102838A
(ko)
|
2006-12-28 |
2009-09-30 |
암브룩스, 인코포레이티드 |
페나진 및 퀴녹살린 치환된 아미노산 및 폴리펩티드
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US20120047586A9
(en)
*
|
2007-10-24 |
2012-02-23 |
Otsuka Chemical Co., Ltd |
Polypeptide having enhanced effector function
|
|
ES2742268T3
(es)
*
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
|
HUE028958T2
(en)
|
2008-02-08 |
2017-01-30 |
Medimmune Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
|
DK2337846T3
(en)
|
2008-09-26 |
2018-03-12 |
Ambrx Inc |
NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES
|
|
EP2385114A4
(en)
|
2008-12-25 |
2012-08-08 |
Univ Tokyo |
CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
|
|
US20120213705A1
(en)
*
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
KR20140059168A
(ko)
|
2011-04-21 |
2014-05-15 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
시신경 척수염 치료용 조성물 및 치료 방법
|
|
US9796754B2
(en)
|
2011-05-27 |
2017-10-24 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
|
|
ES2898854T3
(es)
|
2011-05-27 |
2022-03-09 |
Ambrx Inc |
Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales
|
|
JP2014533659A
(ja)
|
2011-10-24 |
2014-12-15 |
アッヴィ・インコーポレイテッド |
スクレロスチンに対するイムノバインダー
|
|
CA2913370C
(en)
|
2013-05-31 |
2022-12-13 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
CA2926087C
(en)
*
|
2013-10-10 |
2023-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
|
WO2015077503A1
(en)
|
2013-11-22 |
2015-05-28 |
Pharmakea, Inc. |
Autotaxin inhibitor compounds
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
PT3268047T
(pt)
*
|
2015-03-09 |
2023-12-05 |
Heidelberg Pharma Res Gmbh |
Conjugados amatoxina-anticorpo
|
|
TWI703160B
(zh)
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
WO2017136581A1
(en)
*
|
2016-02-02 |
2017-08-10 |
Meditope Biosciences, Inc. |
Anti-egfr antibody drug conjugate
|
|
MX2020002241A
(es)
|
2017-08-28 |
2020-09-03 |
Angiex Inc |
Anticuerpos anti-tm4sf y métodos de uso de los mismos.
|
|
JP2021526837A
(ja)
|
2018-06-12 |
2021-10-11 |
アンジーエックス・インコーポレーテッド |
抗体−オリゴヌクレオチドコンジュゲート
|
|
AU2021244621A1
(en)
|
2020-03-27 |
2022-10-20 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
|
WO2021222783A1
(en)
|
2020-05-01 |
2021-11-04 |
Angiex, Inc. |
Anti-tm4sf1 antibody drug conjugates and methods of using same
|
|
WO2022026915A2
(en)
|
2020-07-31 |
2022-02-03 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
|
EP4204013A4
(en)
|
2020-08-26 |
2025-04-16 |
Angiex, Inc. |
ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USE THEREOF
|